Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

IWWM-11 2022

The 11th International Workshop on Waldenstrom's Macroglobulinemia

27–30 October 2022 | Madrid, Spain

The 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) took place on October 27-30 in Madrid, Spain, and brought world experts in Waldenstrom's Macroglobulinemia (WM) together to discuss updates in the diagnosis, treatment, and biology of WM.

View all videos

What to look forward to at ASH 2022 in the field of Waldenström’s macroglobulinemia

Steven Treon • 28 Oct 2022

Predicting patient response to BTK inhibitors using novel approaches

Steven Treon • 28 Oct 2022

The safety and efficacy of MB-106 for the treatment of Waldenström’s macroglobulinemia

Mazyar Shadman • 29 Oct 2022

FDA approval of teclistamab for R/R multiple myeloma and the value of immunotherapies

Irene Ghobrial • 29 Oct 2022

What to look forward to at ASH 2022 in the field of Waldenström’s macroglobulinemia

Steven Treon • 28 Oct 2022

FDA approval of teclistamab for R/R multiple myeloma and the value of immunotherapies

Irene Ghobrial • 29 Oct 2022

Promising novel treatment approaches in WM: non-covalent BTKis and immunotherapies

Jorge Castillo • 28 Oct 2022

The role of venetoclax in previously treated WM including BTK inhibitor-exposed patients

Jorge Castillo • 28 Oct 2022

Predicting patient response to BTK inhibitors using novel approaches

Steven Treon • 28 Oct 2022

The importance of murine models in WM research

Ruben Carrasco • 28 Oct 2022

An insight into response criteria for Waldenström’s macroglobulinemia

Steven Treon • 28 Oct 2022

Molecular clusters and tumor-immune drivers of IgM monoclonal gammopathies

Patrizia Mondello • 28 Oct 2022